DK3263116T3 - Guldpartikel til anvendelse i terapi til forebyggelse af ardannelse - Google Patents

Guldpartikel til anvendelse i terapi til forebyggelse af ardannelse Download PDF

Info

Publication number
DK3263116T3
DK3263116T3 DK17178814.4T DK17178814T DK3263116T3 DK 3263116 T3 DK3263116 T3 DK 3263116T3 DK 17178814 T DK17178814 T DK 17178814T DK 3263116 T3 DK3263116 T3 DK 3263116T3
Authority
DK
Denmark
Prior art keywords
therapy
formation
gold particle
prevent harm
harm
Prior art date
Application number
DK17178814.4T
Other languages
English (en)
Inventor
Gorm Danscher
Original Assignee
Regold Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regold Aps filed Critical Regold Aps
Application granted granted Critical
Publication of DK3263116T3 publication Critical patent/DK3263116T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/242Gold; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17178814.4T 2016-06-29 2017-06-29 Guldpartikel til anvendelse i terapi til forebyggelse af ardannelse DK3263116T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16176880 2016-06-29

Publications (1)

Publication Number Publication Date
DK3263116T3 true DK3263116T3 (da) 2022-11-14

Family

ID=56345004

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17178814.4T DK3263116T3 (da) 2016-06-29 2017-06-29 Guldpartikel til anvendelse i terapi til forebyggelse af ardannelse

Country Status (3)

Country Link
US (2) US20180000861A1 (da)
EP (2) EP4144355A1 (da)
DK (1) DK3263116T3 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4406543A1 (en) * 2023-01-24 2024-07-31 AuroDerm ApS Gold particle for use in therapy to prevent or reduce the formation of biofilm in patients who are to receive, are receiving, or have received soft tissue filler

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2447614C (en) * 2001-05-25 2009-08-11 Gorm Danscher A method of implanting heavy metal such as nobel metal, e.g. gold, and metal for use in implantation
DK200801559A (en) * 2008-11-11 2010-05-12 Berlock Holding Aps Gold devices for suppressing local inflammation
US10111904B2 (en) * 2013-01-09 2018-10-30 Berlock Aps Micron-sized gold, kit comprising said gold and its use as a non-toxic immune suppressor

Also Published As

Publication number Publication date
EP3263116A1 (en) 2018-01-03
EP4144355A1 (en) 2023-03-08
US20180000861A1 (en) 2018-01-04
US20210093662A1 (en) 2021-04-01
EP3263116B1 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
IL282202A (en) Compositions and methods for personalized neoplasia vaccines
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
DK3046583T3 (da) Viruslignende partikelkonjugater til behandling af tumorer
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
IL243324A0 (en) Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
DK3060237T3 (da) Modificeret omprogrammeringsprotein til anvendelse i behandling af cancer
IL251890A0 (en) Combination immunotherapy approach for treatment of cancer
DK3033102T3 (da) Peptidkonjugerede partikler
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
HUE050095T2 (hu) Anyagcsere-rendellenességek kezelése lófélékben
DK2994533T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3082829T3 (da) Sglt2-inhibitorer til behandlingen af metaboliske lidelser i kattedyr
PL3186244T3 (pl) Analogi dioksolanowe urydyny w leczeniu raka
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK2976072T3 (da) Epinephrinfinpartikler og fremgangsmåder til anvendelse deraf til behandling af tilstande, der reagerer på epinephrin
HUE047062T2 (hu) Angiotenzin II alacsony vérnyomás kombinációs kezelésére
DK3363428T3 (da) Perfusionsdoseringsform
DK3511004T3 (da) Kombineret præparat til behandling af cancer
SI2991633T1 (sl) Terapija za bakteriofagi